PRFX 20-F SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

PRFX ▲ +10.10% at T+20d

SHORT call ✗ call lost -10.10% · α vs SPY +2.64% · entry $2.08 → $2.29

Next anchor: T+60d in 10d

Currently $1.36 · +34.62% from $2.08 entry (call sign-flipped)

Entry anchored
Mar 26, 03:59 PM ET
via Databento tick

T+1d

-9.13%

call +9.13% · α +8.78%

$1.89

settled 3mo ago

T+5d

+21.63%

call -21.63% · α -17.77%

$2.53

settled 2mo ago

T+20d

+10.10%

call -10.10% · α +2.64%

$2.29

settled 7w ago

T+60d

—

call — · α —

—

in 10d

Price Chart

Loading chart...

Executive Summary

PRF Technologies Ltd. (PRFX) reported a significant reduction in net loss from $14.6 million in 2024 to $4.8 million in 2025, driven by lower R&D expenses following the failure of its PRF-110 Phase 3 trial. The company acquired LayerBio, Inc. for $0.6 million and completed the DeepSolar asset acquisition, which is now a key part of its business. Despite a strong balance sheet with $4.1 million in cash, the company's auditor issued a going concern warning due to its history of losses and uncertainty about future funding. The company also faces a material weakness in its internal controls.

Actionable Insight

Investors should be cautious due to the going concern warning and material weakness in internal controls. The company's reduced losses are due to decreased R&D spending, not increased revenue, which raises concerns about its long-term viability. The DeepSolar acquisition could be a key growth driver, but its success is uncertain.

Key Facts

Net loss decreased from $14.6 million in 2024 to $4.8 million in 2025, primarily due to lower R&D expenses.
The company acquired LayerBio, Inc. for $0.6 million and completed the DeepSolar asset acquisition.
The company's auditor issued a going concern warning due to its history of losses and uncertainty about future funding.
The company has a material weakness in its internal controls over financial reporting.
The company raised $3.8 million in net proceeds from its ATM program in 2025.

Financial Impact

The company's net loss decreased by $9.8 million from 2024 to 2025, but it still has an accumulated deficit of $61.3 million.

net losscash and cash equivalentsaccumulated deficit

Risk Factors

The company may not be able to continue as a going concern.
The company has a material weakness in its internal controls over financial reporting.
The company's reduced losses are due to decreased R&D spending, not increased revenue.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

Document	Accession Number
20-F Filing (Primary)	0001178913-26-001782
Exhibit: exhibit_1-1.htm	0001178913-26-001782
Exhibit: exhibit_2-1.htm	0001178913-26-001782
Exhibit: exhibit_12-1.htm	0001178913-26-001782

7 reports for PRFX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for PRFX — sortable, filterable
	Type				Now
May 28, 2026 15d ago	6-K NEUTRAL ★ 3/10	$1.37 $1.86	▲ +35.77%	▲ +35.81%	$1.36 (−0.73%)
May 26, 2026 17d ago	6-K NEUTRAL ★ 4/10	$1.34 $2.02	▲ +50.75%	▲ +49.66%	$1.36 (+1.49%)
May 26, 2026 18d ago	Press Release BULLISH ★ 5/10	$1.34 $2.02	▲ +50.75%	▲ +49.66%	$1.36 (+1.49%)
May 7, 2026 5w ago	6-K BEARISH ★ 7/10	$1.94 $1.58	▲ +18.56%	▲ +20.02%	$1.36 (+29.90%)
Apr 28, 2026 6w ago	Press Release NEUTRAL ★ 4/10	$2.04 $1.97	▼ −3.43%	▼ −5.12%	$1.36 (−33.33%)
Mar 27, 2026 11w ago	6-K MIXED ★ 6/10	$2.08 $2.53	▲ +21.63%	▲ +17.77%	$1.36 (−34.62%)
Mar 26, 2026 11w ago	20-F BEARISH ★ 6/10	$2.08 $2.53	▼ −21.63%	▼ −17.77%	$1.36 (+34.62%)

US Market Status

Market Closed — Opens Mon (48h 56m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access